Every psychedelic and cannabinoid drug trial needs a Schedule I or II compound manufactured to pharmaceutical standards, in controlled quantities, under DEA oversight, before a single patient can be dosed. That layer of the industry rarely makes news. A steady stream of Federal Register filings from a single Texas company shows how much is actually happening inside it. Benuvia Operations, a contract manufacturer based in Round Rock, has filed DEA registration applications covering marijuana extract, tetrahydrocannabinols, ibogaine, mescaline, and lysergic acid diethylamide since early 2025, the most recent an importer application published July 7. Individually, each filing is a procedural notice. Together, they describe a company building out manufacturing capacity across essentially the whole controlled-substance drug-development map at once.
What Benuvia actually is
This is not a speculative newcomer. Benuvia already holds an FDA-approved drug, Syndros, a dronabinol oral solution used for chemotherapy-induced nausea and vomiting and AIDS-related appetite loss, and operates an 83,000-square-foot facility permitted for Schedule I through V controlled substances, cGMP-certified and FDA-registered. Its business is contract development and manufacturing, meaning it makes active pharmaceutical ingredients and finished dosage products for other companies’ drug programs rather than running its own trials. It has commercial supply agreements for dronabinol API with major pharmaceutical partners, a licensing deal to distribute Syndros across the Gulf Cooperation Council region, and Brazilian regulatory certification, an established, revenue-generating operation, not a startup betting everything on one substance.
The pattern in the filings
What the Federal Register record shows is a company steadily widening its DEA authorizations rather than making one big move. A bulk manufacturer application in early 2025. An importer registration for ibogaine and tetrahydrocannabinols filed that October. Another bulk manufacturer application in April 2026 covering LSD, marijuana extract, tetrahydrocannabinols, mescaline, and ibogaine together. And now, filed in May and published July 7, an importer application specifically for marijuana extract, described as bringing in active pharmaceutical ingredients to support the company’s customers. Benuvia’s own public statements confirm the strategic direction: in 2022 the company explicitly entered the psychedelic API market, naming psilocybin, DMT, and MDMA as its initial focus, alongside its established cannabinoid manufacturing base. The DEA filings are that stated strategy showing up, substance by substance, in the regulatory record.
Why a CDMO’s registration list is worth reading
A drug developer’s own trial registrations tell you what a company is testing. A manufacturer’s registration list tells you what an entire slice of the industry expects to need supplied. Benuvia is not itself running a lysergide or ibogaine program; it is positioning to be the vendor multiple such programs can call. That makes its filings a useful aggregate signal, a single company’s authorization list functions as a rough proxy for which Schedule I compounds the broader pipeline is actually moving toward needing manufactured, at pharmaceutical grade, in quantity. Ibogaine and mescaline in particular are compounds with far less clinical infrastructure than psilocybin or MDMA, so registrations covering them suggest the addressable market for these less-developed psychedelics is now substantial enough for a commercial manufacturer to build capacity ahead of demand.
The straddle between desks
Benuvia’s own footprint sits across two of this desk’s verticals at once, an established cannabinoid drug manufacturer, built on an FDA-approved THC product, expanding directly into psychedelic APIs using the same facility and regulatory infrastructure. That is a concrete instance of the convergence this publication exists to track: cannabis and psychedelics are frequently regulated, manufactured, and financed through overlapping infrastructure and overlapping companies, even when they are covered as separate industries.
The caveats
Federal Register filings are procedural notices of intent to import or manufacture, not evidence of executed contracts, production volumes, or which specific drug programs Benuvia is supplying; the desk has no visibility into its actual client list for the psychedelic side of the business. A DEA registration authorizes an activity; it does not by itself indicate commercial success or scale. And a single CDMO’s expansion, however methodical, is one data point about industry-wide manufacturing demand, not proof of it; other API suppliers may be moving in different directions or not at all.
The frame
The psychedelic and cannabinoid industries are covered almost entirely through their clinical and regulatory front end, trial results, FDA designations, DEA scheduling actions aimed at the finished drugs themselves. The manufacturing layer underneath rarely gets attention, which is exactly why it is worth attention. A company that already holds an approved cannabinoid drug and a large DEA-permitted facility spending a year and a half systematically adding LSD, ibogaine, mescaline, and marijuana extract to its authorized substance list is a quiet, structural bet that pharmaceutical-grade supply for this entire compound class is about to matter more than it has. Whichever specific drug programs Benuvia ends up supplying, the buildout itself is a signal the desk will keep watching: the picks-and-shovels side of this industry is expanding in step with, and sometimes ahead of, the headline-grabbing clinical side.